
<html>
<body>

<font FACE="Arial"><b>
<p style="margin-top: 0; margin-bottom: 0" align="right">
<img border="0" src="logo.gif" width="52" height="70">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</p>
<p style="margin-top: 0; margin-bottom: 0" align="right">Chemokine Therapeutics</p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<table border="0" width="100%" id="table1" cellspacing="1">
	<tr>
		<td>
		<p style="margin-top: 0; margin-bottom: 0"><font FACE="Arial"><b>FOR
		IMMEDIATE RELEASE&nbsp;&nbsp; </b></font></td>
		<td>
		<p style="margin-top: 0; margin-bottom: 0" align="right">
		<font FACE="Arial"><b>TSX symbol: CTI</b></font></td>
	</tr>
</table>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">CHEMOKINE COMPLETES
INITIAL PUBLIC OFFERING</p>
</b><i>
<p ALIGN="CENTER" style="margin-top: 0; margin-bottom: 0">- Shares listed on TSX
under the symbol &quot;CTI&quot; -</p>
</i></font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">VANCOUVER, British
Columbia - December 30, 2004 -</b> Chemokine Therapeutics Corp. (TSX:CTI), a
biotechnology company developing drugs in the field of chemokines and cytokines,
today announced its initial public offering, consisting of a new issue of
16,000,000 common shares priced at Cdn$1.00 per share, for gross proceeds of
Cdn$16,000,000. Chemokine Therapeutics' common shares are expected to trade on
the Toronto Stock Exchange under the symbol &quot;CTI&quot; at market opening today.</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">A syndicate of
investment dealers led by Canaccord Capital Corporation and including Jennings
Capital Inc., McFarlane Gordon Inc., and Wellington West Capital Inc.,
participated in the financing. Chemokine has granted the underwriters an option,
exercisable for a period of 60 days from the closing date, to purchase an
additional 2,400,000 common shares to cover over allotments, and for market
stabilization purposes. If the over-allotment is exercised in full, total
maximum gross proceeds of the offering will be approximately Cdn$18,400,000.</font>
</p>
<font SIZE="2"><i>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">This press release
shall not constitute an offer to sell or the solicitation of an offer to buy nor
shall there be any sale of the common shares in any state in which such offer,
solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of such state. Copies of the final prospectus relating
to the offering may be obtained from Chemokine Therapeutics Corp. located at
208-2386 East Mall (UBC), Vancouver, B.C., V6T 1Z3.</p>
</i></font><font FACE="Arial" SIZE="3"><b>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">About Chemokine
Therapeutics Corp. (www.chemokine.net)</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
</b>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Chemokine
Therapeutics Corp. is a biotechnology company focused on chemokines, a family of
small, soluble proteins, structurally related to cytokines. Chemokines play a
role in controlling normal body functions such as immune response and stem cell
development and in the physiological processes of a variety of diseases
including cancer, viral infections, and autoimmune diseases. Chemokine
Therapeutics is developing synthetic chemokines to address a number of diseases
and disorders. Its two drug candidates in clinical trials are CTCE-0214, a
hematological support compound, and CTCE-9908, an anti-metastasis compound. In
addition, Chemokine Therapeutics maintains a drug discovery program to identify
new chemokine-based drug candidates. Pharmaceutical Product Development, Inc. (PPDI)
and Proctor &amp; Gamble Pharmaceuticals, Inc. have signed strategic agreements with
Chemokine Therapeutics to collaborate on research and development.</p>
</font><i><font SIZE="2">
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Statements in this
press release regarding the expected use of the proceeds from the offering of
Chemokine common shares and any other statements, managements' future
expectations, beliefs, goals, plans or prospects constitute forward-looking
statements that involve risks and uncertainties, which may cause actual results
to differ materially from the statements made. For this purpose, any statements
that are contained herein that are not statements of historical fact may be
deemed to be forward-looking statements made pursuant to the safe harbor
provisions of the United States Private Securities Litigation Reform Act of
1995. Without limiting the foregoing, the words &quot;believes&quot;, &quot;anticipates&quot;,
&quot;plans&quot;, &quot;intends&quot;, &quot;will&quot;, &quot;should&quot;, &quot;expects&quot;, &quot;projects&quot;, and similar
expressions are intended to identify forward-looking statements. You are
cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking statements.
These risks include, but are not limited to, those associated with the success
of research and development programs, the regulatory approval process,
competition, securing and maintaining corporate alliances, market acceptance of
the Company's products, the availability of government and insurance
reimbursements for the Company's products, the strength of intellectual
property, financing capability, the potential dilutive effects of any financing,
reliance on subcontractors and key personnel and other risks detailed from
time-to-time in the Company's public disclosure documents or other filings with
the Canadian and U.S. securities commissions or other securities regulatory
bodies. The forward-looking statements are made as of the date hereof, and the
Company disclaims any intention and has no obligation or responsibility, except
as required by law, to update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise.</p>
</font></i><font FACE="Arial" SIZE="3"></font><font FACE="Arial" SIZE="2">
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
<p style="margin-top: 0; margin-bottom: 0">For further information contact:</p>
<p style="margin-top: 0; margin-bottom: 0">&nbsp;</p>
</font>
<table CELLSPACING="1" WIDTH="100%" border="0">
	<tr>
		<td WIDTH="54%" VALIGN="TOP"><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Chemokine
		Therapeutics Corp.</p>
		<p style="margin-top: 0; margin-bottom: 0">Hassan Salari, President and
		CEO, or</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">David Karp,
		Chief Financial Officer</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Phone: (604)
		822-0301</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Fax: (604)
		822-0302</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">E-mail:
		</font><font FACE="Arial">dkarp@chemokine.net</p>
		</font><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Internet:
		</font><font FACE="Arial">www.chemokine.net</font></td>
		<td WIDTH="46%" VALIGN="TOP"><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Investor
		Relations</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Ross Marshall</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">The Equicom
		Group Inc.</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Phone: (416)
		815-0700 (Ext.238)</p>
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">E-mail:
		</font><font FACE="Arial">rmarshall@equicomgroup.com</p>
		</font><font FACE="Arial" SIZE="2">
		<p ALIGN="JUSTIFY" style="margin-top: 0; margin-bottom: 0">Fax: (416)
		815-0080</font></td>
	</tr>
</table>

</body>

</html>

